Harvard Bioscience Inc (HBIO) - Total Assets
Based on the latest financial reports, Harvard Bioscience Inc (HBIO) holds total assets worth $77.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Harvard Bioscience Inc for net asset value and shareholders' equity analysis.
Harvard Bioscience Inc - Total Assets Trend (1998–2024)
This chart illustrates how Harvard Bioscience Inc's total assets have evolved over time, based on quarterly financial data.
Harvard Bioscience Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Harvard Bioscience Inc's total assets of $77.99 Million consist of 35.6% current assets and 64.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.2% |
| Accounts Receivable | $14.87 Million | 11.7% |
| Inventory | $23.25 Million | 18.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.13 Million | 8.8% |
| Goodwill | $56.32 Million | 44.5% |
Asset Composition Trend (1998–2024)
This chart illustrates how Harvard Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HBIO market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harvard Bioscience Inc's current assets represent 35.6% of total assets in 2024, an increase from 13.3% in 1998.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, down from 13.3% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 44.5% of total assets.
Harvard Bioscience Inc Competitors by Total Assets
Key competitors of Harvard Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Harvard Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.81 | 2.06 | 2.46 |
| Quick Ratio | 0.41 | 0.91 | 1.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-10.59 Million | $24.04 Million | $30.65 Million |
Harvard Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Harvard Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -7.8% |
| Total Assets | $126.64 Million |
| Market Capitalization | $24.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Harvard Bioscience Inc's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Harvard Bioscience Inc's assets decreased by 7.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Harvard Bioscience Inc (1998–2024)
The table below shows the annual total assets of Harvard Bioscience Inc from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $126.64 Million | -7.81% |
| 2023-12-31 | $137.37 Million | -5.50% |
| 2022-12-31 | $145.36 Million | -10.46% |
| 2021-12-31 | $162.34 Million | +3.90% |
| 2020-12-31 | $156.25 Million | -5.23% |
| 2019-12-31 | $164.87 Million | -1.91% |
| 2018-12-31 | $168.07 Million | +53.70% |
| 2017-12-31 | $109.35 Million | +1.47% |
| 2016-12-31 | $107.77 Million | -10.36% |
| 2015-12-31 | $120.22 Million | -11.55% |
| 2014-12-31 | $135.92 Million | +0.34% |
| 2013-12-31 | $135.46 Million | +1.48% |
| 2012-12-31 | $133.48 Million | +5.41% |
| 2011-12-31 | $126.63 Million | +1.47% |
| 2010-12-31 | $124.80 Million | +16.38% |
| 2009-12-31 | $107.23 Million | +31.94% |
| 2008-12-31 | $81.27 Million | -17.79% |
| 2007-12-31 | $98.85 Million | +6.03% |
| 2006-12-31 | $93.23 Million | +1.30% |
| 2005-12-31 | $92.03 Million | -34.20% |
| 2004-12-31 | $139.88 Million | +8.92% |
| 2003-12-31 | $128.43 Million | +19.38% |
| 2002-12-31 | $107.58 Million | +30.62% |
| 2001-12-31 | $82.36 Million | +40.05% |
| 2000-12-31 | $58.81 Million | +185.34% |
| 1999-12-31 | $20.61 Million | +185.46% |
| 1998-12-31 | $7.22 Million | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equ… Read more